Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
ACCESSWIRE
04 May 2021, 21:43 GMT+10
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting
OTTAWA, ON / ACCESSWIRE / May 4, 2021 /
Tetra Bio-Pharma Inc. ( Tetra or the Company )(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial evaluating the safety, tolerability and potential efficacy of its veterinary ophthalmic drug, PPP-003v, in the treatment of indolent corneal ulcers in companion animals. Canine indolent corneal ulcers occur frequently in specific breeds of dogs
Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.